US009636344B2

(12) **United States Patent**
Peters et al.

(10) **Patent No.: US 9,636,344 B2**
(45) **Date of Patent: *May 2, 2017**

(54) **SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS**

(71) Applicant: **Bayer Intellectual Property GmbH**, Monheim (DE)

(72) Inventors: **Jan-Georg Peters**, Solingen (DE); **Hans-Christian Militzer**, Odenthal (DE); **Hartwig Müller**, Velbert (DE)

(73) Assignee: **Bayer Intellectual Property GmbH**, Monheim (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/990,350**

(22) Filed: **Jan. 7, 2016**

(65) **Prior Publication Data**

US 2016/0193219 A1 Jul. 7, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/009,599, filed as application No. PCT/EP2012/055600 on Mar. 29, 2012, now abandoned.

(30) **Foreign Application Priority Data**

Apr. 5, 2011 (EP) 11161111

(51) **Int. Cl.**
A61K 31/5377 (2006.01)
C07D 487/04 (2006.01)
A61K 45/06 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/5377*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 487/04*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/5377
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,140,707	A	2/1979	Cleare et al.
5,521,184	A	5/1996	Zimmermann
5,665,772	A	9/1997	Cottens et al.
7,511,041	B2	3/2009	Shimada et al.
8,129,386	B2	3/2012	Shimada et al.
8,466,283	B2	6/2013	Hentemann et al.
8,568,720	B2	10/2013	Morichika et al.
8,859,572	B2	10/2014	Hentemann et al.

FOREIGN PATENT DOCUMENTS

DE	2329485		12/1973
EP	0 564 409		10/1993
EP	2 168 582	A1	3/2010
EP	2168582	A1	3/2010
NL	7307863		12/1973
WO	94/09010	A1	4/1994
WO	02/20519	A1	3/2002
WO	2004/029055	A1	4/2004
WO	2008/070150	A1	6/2008
WO	2010/034414	A1	4/2010
WO	2010/070370	A1	6/2010
WO	2011/128407	A2	10/2011
WO	2012/062748	A1	5/2012

OTHER PUBLICATIONS

The Merck Index: "An encyclopedia of chemicals, drugs, and biological" 15th Edition, 2013, pp. 910-911 and p. 718.

Carlos Correa. "Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective"; University of Buenos Aires; published by International Centre for Trade and Sustainable Development (ICTSD), World Health Organization (WHO), Switzerland 2007, p. 9.

Giron, D., "Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates," Thermochimica Acta, 1995, 248:1-59.

Torbett Neil E et al., "A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K", Biochem. J., 2008, 415:97-110.

U.S. Appl. No. 14/500,484, filed Sep. 29, 2014, Examiner: Gembeh, Shirley V.

U.S. Appl. No. 14/009,751, filed May 19, 2014, Examiner: Rao, Savitha M.

U.S. Appl. No. 13/908,566, filed Jun. 3, 2013, Examiner Stone, Christopher R.

U.S. Appl. No. 12/812,911, filed Apr. 18, 2011, now U.S. Pat. No. 8,859,572, issued Oct. 14, 2014.

Primary Examiner — Noble Jarrell
Assistant Examiner — John S Kenyon
(74) *Attorney, Agent, or Firm* — Morrison and Foerster LLP

(57) **ABSTRACT**

The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II):

(II)



• 2 HCl

or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.

4 Claims, 7 Drawing Sheets